Search the Newsreel

RA Capital discloses 6.2% BioCryst (BCRX) holding of 15.8M shares

RA Capital Management, L.P. and its affiliated entities have reported a passive ownership stake of 6.2% in BioCryst Pharmaceuticals, Inc. This holding, as of June 30, 2026, comprises 15,827,186 shares of common stock, with RA Capital Healthcare Fund, L.P. directly owning these shares. The …

Rare Earth Stocks Soar on Friday: MP Materials Up 8%, USA Rare Earth Up 9%, NioCorp Up 3%. What’s Behind the Jump?

Quick Read MP Materials surged 8% and USA Rare Earth jumped 9% Friday on trader speculation about U.S. tariff support, with no confirmed catalyst. Rare earth stocks price in tariff probability before any announcement, rewarding holders if policy lands but punishing them sharply if …

Research Analysts Issue Forecasts for BCRX Q4 Earnings

Wedge Capital Management L L P NC Acquires Shares of 380,801 BioCryst Pharmaceuticals, Inc. $BCRX

Wedge Capital Management L.L.P. NC recently purchased 380,801 shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for approximately $3.8 million, now holding 0.15% of the company. Institutional investors collectively own 85.88% of the biotechnology firm. BioCryst Pharmaceuticals reported strong quarterly earnings, beating analyst estimates with $0.30 …

KIOCL Q1 Results FY27: Net Loss Rs 15 Cr, Revenue Rs 158 crore

BioCardia (BCDA) CEO Peter Altman purchases 1,900 shares at $0.92 average price

BioCardia's President and CEO, Peter Altman, recently purchased 1,900 shares of the company's common stock at a weighted average price of $0.92 per share. This open-market transaction, which occurred on August 13, 2026, increased his direct holdings to 375,785 shares. The purchase was not …

Why Did BioCryst Pharmaceuticals (BCRX) Shares Climb After Its Latest Update?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. BioCryst Pharmaceuticals (BCRX) is back in focus after raising its full year 2026 revenue …

KIOCL revenue rises 67% in Q1FY27, but net loss widens to ₹155 crore

BioCryst Pharmaceuticals (BCRX) Stock Looks Cheap Even After A 53% Gain

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. BioCryst Pharmaceuticals stock has put up a 53.0% gain over the past three years, yet the current valuation checks still lean on the …

BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulatory Wins in Japan and US ...

BioCardia Inc. (BCDA) reported its Q2 2026 earnings, highlighting significant regulatory progress in Japan and the US for its cardiac cell therapy and Helix delivery catheter. The company received positive feedback from both the PMDA and FDA, supporting its path to market approval, and …

BioCardia Q2 loss narrows 67.5% YoY; regulatory milestones advance

BioCardia Inc. reported a significant narrowing of its Q2 2026 net loss to $1.6 million, an improvement of 21.3% year-over-year, beating EPS estimates by 27.78%. The company also announced key regulatory advancements, including PMDA support for a Q4 2026 CardiAMP submission in Japan and …

Will Strong Q2 Results and Monetization Moves Change RioCan's (TSX:REI.UN) Narrative?

Earnings call transcript: BioCardia posts q2 2026 loss beat, shares rise after hours

BioCardia (BCDA) reported a smaller-than-expected Q2 2026 loss of $0.13 per share, beating analyst estimates of $0.18, and its shares rose in after-hours trading. The company highlighted significant regulatory progress, including support from Japan's PMDA for a Shonin submission for CardiAMP cell therapy and …

Is BioCardia Inc (BCDA) Facing Financial Challenges After Q2 Ear

BioCardia, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

BRIEF-BioCardia, Inc. Q2 Net Income USD -1.613 Million

BioCardia, Inc. reported a Q2 net income of USD -1.613 million. The article from Reuters provides a brief update on the company's financial performance. Full access to this and other news sources is available through a TradingView subscription.

BioCardia reports Q2 2026 net loss narrows to $1.6M; cash $4.1M with runway into 2027

BioCardia (BCDA) reported a net loss of $1.6 million for Q2 2026, a reduction from $2.0 million in the prior year, and holds $4.1 million in cash, projecting a runway into 2027. The company is actively pursuing regulatory approvals in Japan and the US …

BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results

BioCardia, Inc. reported its second-quarter 2026 financial results, highlighting significant progress in regulatory discussions with agencies in Japan and the U.S. The company achieved important milestones including PMDA support for CardiAMP Cell Therapy submission in Japan, FDA acknowledgement that the CardiAMP HF II trial …

BioCryst (BCRX) Q2 2026 Earnings Call Transcript

BioCryst Pharmaceuticals reported strong Q2 2026 results, with total revenue up 45% year-over-year to $218.3 million and ORLADEYO net revenue increasing 10% to $158.2 million. The company is transitioning to an external innovation model, closing its Birmingham research facility, and has launched its pediatric …

Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

Shares of BioCryst Pharmaceuticals (BCRX) have gained 6.2% over the past four weeks to close the last trading session at $10.34, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. …

William Blair Maintains NioCorp Developments(NB.US) With Buy Rating

William Blair has reiterated its Buy rating on NioCorp Developments (NB.US). This indicates a continued positive outlook from the firm regarding NioCorp Developments' stock performance and prospects.

BioCryst Pharmaceuticals, Inc. (BCRX) Investor Outlook: Exploring a 111.57% Potential Upside

BioCryst Pharmaceuticals, Inc. (BCRX) presents a significant growth opportunity in the biopharmaceutical sector, driven by its focus on rare diseases and a strong pipeline including ORLADEYO. Analysts project a substantial 111.57% potential upside with an average target price of $20.82, fueled by robust revenue …

NioCorp expands Elk Creek into eight-mineral project with 40-year mine life

NioCorp Developments Ltd. released an updated feasibility study for its Elk Creek Critical Minerals Project, significantly expanding its scope to produce eight critical minerals over a 40-year mine life. The project now boasts improved economics, with a pre-tax net present value of USD$4.1 billion, …

NioCorp Elk Creek Feasibility Study 2026: NPV $4.1B, 8 Critical Minerals - News and Statistics

NioCorp Developments has released a revised feasibility assessment for its Elk Creek critical minerals project in Nebraska, revealing a pre-tax NPV of $4.1 billion and a 40-year mine life. The project is expected to produce eight critical minerals, addressing U.S. reliance on foreign sources …

Updated feasibility study gives NioCorp’s Elk Creek critical minerals project a $4B valuation

NioCorp Developments has released an updated feasibility study for its Elk Creek critical minerals project in Nebraska, valuing it at over $4 billion. The study outlines a 40-year operation producing eight critical minerals, including ferroniobium, scandium, titanium, and several rare earth oxides. This project …

NB Bancorp, Inc. Common Stock (NASDAQ: NBBK) Stock Price, News & Analysis

BioCryst Pharmaceuticals (BCRX) Could Be 54% Undervalued Following Strong Earnings Guidance

BioCryst Pharmaceuticals (BCRX) is potentially 54% undervalued, with a fair value estimated at $21.30 per share against a last close of $9.84. This outlook follows a strong Q2 2026 report showing higher revenue, improved net income, and a raised full-year revenue forecast, coupled with …

BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 6% - What's Next?

BioCryst Pharmaceuticals (NASDAQ:BCRX) saw its stock price increase by 6% in mid-day trading following strong quarterly results, where the company exceeded EPS and revenue expectations. Analysts maintain a "Moderate Buy" consensus with an average price target of $20.60, despite varied individual ratings. Institutional investors …

Former NioCorp general counsel leads Latitude's new Denver office

Latitude, a flexible legal talent company, has opened a new regional office in Denver, led by founding partner David Hamm. Hamm, a former general counsel for NioCorp Developments Ltd. and a Big Law attorney, will provide experienced legal professionals for contract engagements, secondments, and …

Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options

Investors in BioCryst Pharmaceuticals, Inc. BCRX need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 18, 2026 $2 Put had some of the highest implied volatility of all equity options today. What …

AudioCodes EVP, Chief Business Officer Lior Aldema sells 2,812 shares worth $28,066

Lior Aldema, EVP and Chief Business Officer of AudioCodes, sold 2,812 ordinary shares on August 10 for a total of $28,066, at a weighted average price of $9.98 per share. Following this transaction, his beneficial ownership in the company stands at 104,065 ordinary shares. …

Insider Selling: AudioCodes (NASDAQ:AUDC) EVP Sells 2,812 Shares

AudioCodes (NASDAQ:AUDC) Executive Vice President Lior Aldema sold 2,812 shares of the company's stock for a total of $28,063.76. This sale reduced his holdings by 2.63% and was conducted under a pre-arranged Rule 10b5-1 trading plan. The company recently reported better-than-expected quarterly earnings and …

AudioCodes Ltd (AUDC) CFO pre-planned sale: 1,875 shares at about $10 each

AudioCodes Ltd's CFO, Baruch Niran, sold 1,875 Ordinary Shares on August 10, 2026, at a weighted average price of $9.9906 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025, leaving him with 99,375 shares. The shares …